Within the “diagnostics and tools” track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in development of microRNA-based diagnostics (miRview) for various cancers as well as for the identification of the origin of [...]
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche is a nascent paradigm for exploiting breakthroughs in [...]
Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for [...]
Helicos made a timely entrance in the race for genetic analysis systems with their HeliScope “true single molecule sequencer” (tSMS), “the first DNA microscope”. The technology was positioned as an alternative to DNA amplification, requiring less starting material while eliminating biases, complexity and errors.In addition,SMS technologies supposedly have the advantage of ultra long reads.An IPO [...]
Complete Genomics 2/18/10 Molecular Diagnostics and Genomics “Powering large-scale human genome studies”. Private Company Summary Complete Genomics(CGI) provides high quality, affordable DNA sequencing for commercial- scale research of the genetic mechanisms underlying drug responses and complex diseases. Customers receive assembled sequences and variant reports [...]
Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions (Personalized Medicine, Pharmacogenomics). In 2004 Genomic Health launched [...]
